Pioneers in Plasma Surgery & Medicine - Over 35,000 Procedures & Counting

CANADY COLD PLASMA™ TECHNOLOGY
FOR THE TREATMENT OF CANCER

IN 2019 IN THE U.S.,

The American Cancer Society estimates 1,762,450 new cancer cases and 600,920 cancer deaths.

Estimated New Cancers (2019) – ACS

TUMOR REMOVAL

Often treatment protocol dictates surgical removal of the cancerous tumor along with a “margin” of healthy tissue to ensure all of the cancer has been removed.

CANCEROUS MARGINS

When a surgeon excises cancerous tissue there is never a “guarantee” that there isn’t microscopic cancer cells left behind at the surgical margins.

THE SOLUTION:

CANADY COLD PLASMA™ TECHNOLOGY

CANADY HELIOS™ COLD PLASMA SCALPEL and CP-1000 GENERATOR

USMI sees tremendous potential for the application of Canady Cold Atmospheric Plasma in the treatment of the surgical site immediately following the removal of a cancerous tumor.

USMI is the first company in the world to integrate a high-frequency electrosurgical generator and plasma gas to deliver Cold Atmospheric Plasma (CAP) for the selective treatment of Cancer.
(US Patent No. 10,023,858 B2, July 2019)

The Canady Cold Plasma™ spray is a non-thermal process that triggers chemical-molecular changes in cancer cells, leading to apoptosis (cell death), while healthy human tissue and cells are left unharmed.

THE CANADY COLD PLASMA™ PROCEDURE

 

Cancerous Tumor Located in Breast


Tumor Removed with Canady Hybrid Plasma™ Scalpel


Tumor Cavity and Margins Sprayed with Canady Helios™ Cold Plasma for 2-6 minutes depending on cancer type.


Microscopic Cancer Cells are targeted with the Canady Helios™ Cold Plasma

COLD PLASMA VIDEOS

USMI’s Cold Plasma Technology Featured on Fox News

USMI’s Cold Plasma Trailer

Amelda’s Story: Inoperable Liver Cancer